Literature DB >> 18627331

Nitric oxide: new evidence for novel therapeutic indications.

Sunil J Wimalawansa1.   

Abstract

BACKGROUND: Nitric oxide (NO) deficiency is implicated in many pathophysiological processes in mammals. NO is a ubiquitous molecule involved in multiple cellular functions. Uncontrolled or inappropriate production of NO may lead to several disease states including septic shock, rheumatoid and inflammatory arthropathies, and expansion of cerebral damage after stroke. However, to date, there are no therapeutic agents available that can overcome these conditions. Similarly, underproduction of NO by NO synthase or enhanced breakdown of NO also leads to diseases such as hypertension, ischemic conditions, pre-eclampsia, premature delivery, among others. NO donor therapies are indicated in these conditions.
RESULTS: Nitroglycerin and nitrates (NO donors) have been used as therapeutic agents for the past century, particularly to treat vascular disease, and the only significant adverse effects are headaches. NO donors are highly cost-effective and have beneficial effects in multiple body systems. When the body cannot generate NO via NO synthase or due to rapid turnover leading to inadequate amounts of NO available for biological homeostasis, administration of exogenous NO, or prolongation of the actions of endogenous NO, are practical ways to supplement NO.
CONCLUSION: Recipients of such therapy include patients with angina pectoris, coronary artery disease, hypertension, osteoporosis, gastrointestinal motility disorders, pregnancy-related disorders including premature delivery, pre-eclampsia, vulvodynia, and erectile dysfunction in men. Postmenopausal NO deficiency is rectified with hormone replacement therapy, which enhances local production of NO. Declining local NO production secondary to estrogen deficiency in postmenopausal women and perhaps in older men could be one of the reasons for age-related increased incidences of cardiovascular events and sexual dysfunction. Thus, in addition to supplementation of NO compounds in acute situations like alleviating angina and erectile dysfunction, chronic NO therapy is cost-effective in decreasing cardiovascular events, and improving the urogenital system and skeletal health.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18627331     DOI: 10.1517/14656566.9.11.1935

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  16 in total

1.  Inhibitory Effects of JEUD-38, a New Sesquiterpene Lactone from Inula japonica Thunb, on LPS-Induced iNOS Expression in RAW264.7 Cells.

Authors:  Xiaoqing Wang; Sheng-An Tang; Ran Wang; Yuling Qiu; Meihua Jin; Dexin Kong
Journal:  Inflammation       Date:  2015       Impact factor: 4.092

2.  Nitric oxide-loaded echogenic liposomes for nitric oxide delivery and inhibition of intimal hyperplasia.

Authors:  Shao-Ling Huang; Patrick H Kee; Hyunggun Kim; Melanie R Moody; Stephen M Chrzanowski; Robert C Macdonald; David D McPherson
Journal:  J Am Coll Cardiol       Date:  2009-08-11       Impact factor: 24.094

3.  The Protective and Therapeutic Effect of Exclusive and Combined Treatment with Alpha-ketoglutarate Sodium Salt and Ipriflavone on Bone Loss in Orchidectomized Rats.

Authors:  R P Radzki; M Bieńko; R Filip; S G Pierzynowski
Journal:  J Nutr Health Aging       Date:  2016       Impact factor: 4.075

4.  Hepatic gene expression profiling of 5'-AMP-induced hypometabolism in mice.

Authors:  Zhaoyang Zhao; Takao Miki; Anita Van Oort-Jansen; Tomoko Matsumoto; David S Loose; Cheng Chi Lee
Journal:  Physiol Genomics       Date:  2011-01-11       Impact factor: 3.107

5.  NO Photoreleaser-Deoxyadenosine and -Bile Acid Derivative Bioconjugates as Novel Potential Photochemotherapeutics.

Authors:  Maria Luisa Navacchia; Aurore Fraix; Nicola Chinaglia; Eleonora Gallerani; Daniela Perrone; Venera Cardile; Adriana C E Graziano; Massimo L Capobianco; Salvatore Sortino
Journal:  ACS Med Chem Lett       Date:  2016-08-18       Impact factor: 4.345

6.  Effects of slow, sustained, and rate-tunable nitric oxide donors on human aortic smooth muscle cells proliferation.

Authors:  Hao Yu; Thomas J Payne; Dillip K Mohanty
Journal:  Chem Biol Drug Des       Date:  2011-08-03       Impact factor: 2.817

7.  Effect of topically applied sildenafil citrate on wound healing: experimental study.

Authors:  Koray Gürsoy; Melike Oruç; Yüksel Kankaya; Mustafa Gürhan Ulusoy; Uğur Koçer; Duygu Kankaya; Reyhan Neslihan Gürsoy; Özge Çevik; Elmas Öğüş; Vildan Fidanci
Journal:  Bosn J Basic Med Sci       Date:  2014-08-16       Impact factor: 3.363

8.  Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss.

Authors:  Sunil J Wimalawansa; Julia P Grimes; Alan C Wilson; Donald R Hoover
Journal:  J Clin Endocrinol Metab       Date:  2009-06-23       Impact factor: 5.958

9.  Cucurbitacin L 2-O-β-Glucoside Demonstrates Apoptogenesis in Colon Adenocarcinoma Cells (HT-29): Involvement of Reactive Oxygen and Nitrogen Species Regulation.

Authors:  Siddig Ibrahim Abdelwahab; Loiy Elsir Ahmed Hassan; Amin M S Abdul Majid; Sakina M Ahmed Yagi; Syam Mohan; Manal Mohamed Elhassan Taha; Syahida Ahmad; Cheah Shiau Chuen; Putri Narrima; Mohd Mustafa Rais; Suvitha Syam; Bushra Abdulkarim Moharam; A Hamid A Hadi
Journal:  Evid Based Complement Alternat Med       Date:  2012-02-26       Impact factor: 2.629

Review 10.  Hydrogen sulfide and the vasculature: a novel vasculoprotective entity and regulator of nitric oxide bioavailability?

Authors:  Matthew Whiteman; Philip K Moore
Journal:  J Cell Mol Med       Date:  2009-03       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.